Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Johnson’s Critique Of Inpatient Proposal Mirrors Med-Tech Complaints

This article was originally published in The Gray Sheet

Executive Summary

A powerful member of Congress added a measure of support last week to the device industry's position that CMS' proposal to change hospital inpatient payments from a charge-based to a cost-based system relies too much on data that serves to penalize new technology
Advertisement

Related Content

CMS’ Change Of Heart On Inpatient Rule Is Positive News For Cardiac Firms
CMS’ Change Of Heart On Inpatient Rule Is Positive News For Cardiac Firms
Senate, House Members Weigh In On Delay Of Inpatient Payment Overhaul
Few Changes Likely In Outpatient Rule; AdvaMed Wants Reform
Few Changes Likely In Outpatient Rule; AdvaMed Wants Reform
After Months Of Buildup, Inpatient Proposal Comments Are In
Pressure Grows On CMS To Delay Overhaul Of Inpatient Payments
Pressure Grows On CMS To Delay Overhaul Of Inpatient Payments
Advertisement
UsernamePublicRestriction

Register

MT023683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel